Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations

Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations

Abstract Background Despite the remarkable advances in the early diagnosis and treatment, overall 5-year survival rate of patients with pancreatic cancer is less than 10%. Gemcitabine (GEM), a cytidine nucleoside analogue and ribonucleotide reductase inhibitor, is a primary option for patients with...

Full description

Bibliographic Details
Main Authors: Toshinori Ozaki, Meng Yu, Danjing Yin, Dan Sun, Yuyan Zhu, Youquan Bu, Meixiang Sang
Format: Article
Language:English
Published: BMC 2018-03-01
Series:BMC Cancer
Subjects:
Gemcitabine
Mutant p53
p53 family
RUNX2
Online Access:http://link.springer.com/article/10.1186/s12885-018-4217-9

Internet

http://link.springer.com/article/10.1186/s12885-018-4217-9

Similar Items